The PBM is removing four products and adding one product back to its standard control formulary.
Effective Oct. 1, 2022, CVS Caremark is removing four generic drugs from its Standard Control Formulary and adding back one branded therapy for the commercial segment that was previously removed. A CVS Caremark spokesperson did not provide a reason for the newest changes.
“Our template formularies remain critical tools in helping clients save money as they recover from the economic impacts of COVID-19, while continuing to provide affordable prescription drug benefits to their members,” the spokesperson told Formulary Watch.
Added back to the formulary is Novartis’s Zortress (everolimus), which is used to prevent transplant rejection in those who have received a kidney or liver transplant. The average retail price is $1,919.28 for 120 tablets, according to GoodRx, with the lowest price of $561.10.
The updated list also shows Bristol Myers Squibb’s Eliquis (apixaban) as being a covered therapy. The spokesperson said Eliquis had been added back onto the formulary effective July 1, 2022, and the updated list now reflects this. Eliquis had been excluded from the drug list earlier this year. The CVS Caremark spokesperson said they was able to secure a lower net cost through negotiations with the manufacturer.
Related: CVS Caremark Drops Several Products from Drug List
Two of the removals include: betamethasone dipropionate ointment, which is a glucocorticoid steroid, and clobetasol emulsion foam ointment, a steroid, both used to treat a variety of skin conditions, such as eczema, dermatitis, allergies and rash.
The formulary list shows that covered medications include the topical Bryhali (halobetsol), a highly potent steroid developed by Ortho Dermatologics, and several other medium- and high-potency generic steroids that are used to treat some of the same conditions. Additionally, while clobetasol emulsion foam ointment has been removed from the formulary, CVS Caremark still provides coverage for clobetasol foam ointment and gel.
Two other removals include:
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More